Harmony Biosciences remains down since the company announced its CEO transition. Will an upcoming readout change that?
Technical indicators have turned bullish for the Barron’s Investor Circle stock picks.
Detailed price information for Harmony Biosciences Holdings Inc (HRMY-Q) from The Globe and Mail including charting and trades.
Detailed price information for Harmony Biosciences Holdings Inc (HRMY-Q) from The Globe and Mail including charting and trades.
Harmony Biosciences stock took a tumble Monday after its announced the transition of current CEO Jeffrey Dayno at the end of the year.
Harmony Biosciences (HRMY) said Monday that Peter Anastasiou, currently chief operating officer, has
Harmony Biosciences Holdings has delivered a 1 year share return that catches the eye, which naturally raises a question for investors who focus on earnings. Is the current US$39.34 price a fair reflection of what the business is generating today, or has sentiment moved ahead of the profit picture? The stock is up 48.1% over the past year, which puts real pressure on the question of whether recent earnings are carrying more of the load than before. The business relies heavily on monetizing a...
PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company’s investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress being held from September 5-9, in Athens, Greece. The company is investigating EPX-100 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome in the ongoing ARGUS and LIGHTHOUSE trials, respectively. These trials are current
PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony BiosciencesHarmony Biosciences
Harmony Biosciences (HRMY) has an average rating of overweight and mean price target of $47.36, acco
This is the newest page. Registered accounts read further back.